FDA declares semaglutide shortage over, spelling end to compounded GLP-1 market
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, is no longer in short supply. | The demand for weight loss drugs is not slowing down,
Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on notice
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.
Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...
22hon MSN
A doctor from the University of Palermo in Italy has published a case study of an adult cocaine user who experienced reduced ...
A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.
Jacobs Solutions CEO Bob Pragada joins 'Squawk Box' to discuss the building opportunities of life science facilities to meet ...
Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...
GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
As GLP-1 medications such as Ozempic, Mounjaro and Wegovy rise in popularity, so do concerns over their side effects.
This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...
ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control, and adding savory flavors are ways that ...
Taking tiny doses of GLP-1 medication has been touted for weight management, perimenopause symptoms, even longevity. But is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback